This site is intended for US Healthcare Professionals


Educational Materials for
Healthcare Providers

The CAPRELSA® (vandetanib) Tablets REMS Program provides important information on the risks associated with CAPRELSA as well as information on recommended monitoring and management of patients receiving CAPRELSA.

In order to become a certified prescriber, you must review the following educational materials:

CAPRELSA REMS Prescriber Training Pamphlet pdf, or CAPRELSA REMS Prescriber Training Slide Deck pdf, and CAPRELSA Prescribing Information pdf


Please see the Prescribing Information for CAPRELSA, including boxed WARNING. pdf


Only certified prescribers can prescribe CAPRELSA.

Enroll in the CAPRELSA REMS Program to become certified to prescribe.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit or call 1-800-FDA-1088.

CAPRELSA is a registered trademark of Genzyme Corporation.